Zepbound vs Wegovy
The two weight-management brands head-to-head: Zepbound (tirzepatide, dual GIP + GLP-1) vs Wegovy (semaglutide, GLP-1). In a 2025 trial, tirzepatide produced greater average weight loss.
At a glance
| Attribute | Zepbound | Wegovy |
|---|---|---|
| Active drug | tirzepatide | semaglutide |
| Drug class | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA-approved for | Chronic weight management | Chronic weight management |
| How it's taken | Once-weekly injection | Once-weekly injection or once-daily tablet |
| Maker | Eli Lilly | Novo Nordisk |
The short version
Zepbound and Wegovy are the two most-prescribed injectables FDA-approved for chronic weight management (Saxenda, daily liraglutide, is a third). Zepbound is tirzepatide (Eli Lilly), a dual GIP + GLP-1 agonist; Wegovy is semaglutide (Novo Nordisk), a GLP-1 agonist. This is the closest thing to an apples-to-apples GLP-1 weight-loss comparison.
The key difference
Zepbound's dual mechanism is the main difference, and it showed up in outcomes: in SURMOUNT-5 (2025), a direct head-to-head, tirzepatide produced greater average weight loss than semaglutide. Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity — Wegovy is not.
What the trials showed on weight
In their pivotal trials, Zepbound (tirzepatide 15 mg) averaged about 20–21% body-weight reduction (SURMOUNT-1) and Wegovy (semaglutide 2.4 mg) about 15% (STEP 1); the SURMOUNT-5 head-to-head favored tirzepatide. These are averages, not promises — side effects, cost, and coverage differ and results vary.
Bottom line
For average weight loss, the evidence favors Zepbound, including a direct head-to-head. But Wegovy has a longer track record and cardiovascular-outcome data, and tolerability and cost vary — the choice is individualized with a clinician. Not medical advice.
Frequently asked
- Is Zepbound better than Wegovy for weight loss?
- In SURMOUNT-5, a 2025 head-to-head trial, tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy). But averages hide individual variation, and Wegovy has cardiovascular-outcome data; the best choice depends on your health, tolerability, and cost. This is general information, not medical advice.
- Are Zepbound and Wegovy the same drug?
- No. Zepbound is tirzepatide (a dual GIP + GLP-1 agonist); Wegovy is semaglutide (a GLP-1 agonist). Both are once-weekly injections approved for chronic weight management, but they're different molecules from different makers.
- Which is cheaper, Zepbound or Wegovy?
- Both are high-cost brand-name injectables and pricing depends heavily on insurance coverage, manufacturer savings programs, and pharmacy. We don't quote live prices — check current pricing and your plan's coverage directly, and ask about manufacturer savings cards.
Compare more GLP-1 options
Sources
- DailyMed — FDA drug labels (search a brand to read its prescribing information) ↗
- Wilding et al., STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity — NEJM 2021 (PubMed) ↗
- Jastreboff et al., SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity — NEJM 2022 (PubMed) ↗
- Aronne et al., SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — NEJM 2025 (PubMed) ↗
General information, not medical advice, and not a substitute for your clinician. Efficacy figures are pivotal-trial averages — individual results, side effects, and cost vary. Only a licensed healthcare professional can choose, start, switch, or dose these medicines.